Atormac
brintellex
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 6680  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
    Next article
    Previous article
    Table of Contents

 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1154    
    Printed38    
    Emailed0    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal

 

 
Year : 1996  |  Volume : 44  |  Issue : 4  |  Page : 177--182

Treatment of Parkinson's disease.


Department of Neurology, Sree Chitra Tirunal Institute of Medical Sciences and Technology, Thiruvananthapuram - 695 011, India

Correspondence Address:
A Vijayaraghavan
Department of Neurology, Sree Chitra Tirunal Institute of Medical Sciences and Technology, Thiruvananthapuram - 695 011
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 29542525

Rights and PermissionsRights and Permissions

Inspite of extensive research the ideal drug therapy for idiopathic Parkinson's disease (PD) and its optimal timing remain uncertain. Levodopa still is the mainstay of therapy for PD. Little evidence exists to incriminate early institution of levodopa therapy in development of motor fluctuations and dyskinesias in PD. These complications are probably a consequence of disease progression, and resultant inability to synthesise and store dopamine, and buffer the variability in dopamine availability. Therefore, withholding levodopa therapy until late stage of the disease is not warranted. Dopa agonists provide only a short-term benefit. The neuroprotective effect of selegeline remains to be established. There is not enough evidence to justify the current practice of initiating treatment for PD patients with expensive polypharmacy. Research into the development of inexpensive levodopa containing preparations needs to be encouraged.






[PDF Not available]*


        
Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow